{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:31:26Z","timestamp":1787841086580,"version":"build-2784847793"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Palbociclib, a CDK4\/6 inhibitor, was approved by FDA in 2015 for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). It was approved based on clinical benefits observed in PALOMA-1\/TRIO-18 and PALOMA-2 Trial of Palbociclib. Despite its benefits in clinical studies, the data related to real-world outcomes are limited. This retrospective real-world observational study was designed to evaluate effectiveness of Palbociclib among Indian patients diagnosed with HR+\/HER2- ABC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The study was conducted across six hospitals and enrolled 150 patients treated with Palbociclib and aromatase inhibitors or Fulvestrant from December 2016 to May 2021. It focused on the analysis of clinical characteristics, treatment patterns, and clinical outcomes of patients receiving Palbociclib combinations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of the 150 enrolled patients, 97% had ABC and 70% received Palbociclib as first-line therapy. The majority of patients (94.6%) received 125 mg\/day Palbociclib as starting dose. 25.3% of patients required at least one dose adjustment. Overall, real-world response rate and the real-world clinical benefit rate across treatment lines were 68% and 75.3%, respectively. The overall persistence rate during the first six months of treatment was 62.9% for the first-line and 48.9% for the second-line therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In India, where patients with BC often present at advanced stages due to late diagnosis and limited access to targeted therapies, Palbociclib offers a well-tolerated and effective treatment option. Real-world data from Indian patients highlight its role in bridging treatment gaps, making personalized therapy more accessible, and aligning treatment strategies with global standards.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_1552_25","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T13:06:41Z","timestamp":1774876001000},"page":"97-103","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Real-world treatment patterns and outcomes in Indian patients with HR+\/HER2- advanced breast cancer treated with palbociclib"],"prefix":"10.4103","volume":"22","author":[{"given":"Senthil","family":"Rajappa","sequence":"first","affiliation":[{"name":"Medical Oncology, Basavatarakam Indo American Cancer Hospital and RI, Nandi Nagar, Banjara Hills, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Bapna","sequence":"additional","affiliation":[{"name":"Medical Oncology, Bhagwan Mahaveer Cancer Hospital and Research Centre, Jaipur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devavrat","family":"Arya","sequence":"additional","affiliation":[{"name":"Medical Oncology, Max Super Speciality Hospital, Saket, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirag","family":"Desai","sequence":"additional","affiliation":[{"name":"Medical Oncology, Hemato Oncology Clinic, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manasi","family":"Shah","sequence":"additional","affiliation":[{"name":"Medical Oncology, HCG Cancer Centre, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenu","family":"Walia","sequence":"additional","affiliation":[{"name":"Medical Oncology, Max Super Speciality Hospital, Patparganj, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"R1-20260331","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20260331","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5306\/wjco.v13.i3.209","article-title":"Breast cancer in India: Present scenario and the challenges ahead","volume":"13","author":"Mehrotra","year":"2022","journal-title":"World J Clin Oncol"},{"key":"R3-20260331","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10549-024-07264-3","article-title":"Burden of female breast cancer in India: Estimates of YLDs, YLLs, and DALYs at national and subnational levels based on the national cancer registry programme","volume":"205","author":"Kulothungan","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"R4-20260331","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ctrv.2016.08.008","article-title":"Endocrine treatment in breast cancer: Cure, resistance and beyond","volume":"50","author":"Tryfonidis","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"4 Suppl","key":"R6-20260331","article-title":"Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2 negative advanced breast cancer: Efficacy and safety updates with longer follow-up across patient subgroups","volume":"78","author":"Rugo","year":"2018","journal-title":"Cancer Res"},{"key":"R7-20260331","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"key":"R10-20260331","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"R11-20260331","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1634\/theoncologist.2017-0072","article-title":"Palbociclib combined with fulvestrant in premenopausal women with advanced breast cancer and prior progression on endocrine therapy: PALOMA-3 results","volume":"22","author":"Loibl","year":"2017","journal-title":"Oncologist"},{"key":"R12-20260331","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41523-022-00479-x","article-title":"Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+\/HER2- metastatic breast cancer","volume":"8","author":"Rugo","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"R13-20260331","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R14-20260331","article-title":"Real-world treatment patterns and clinical outcomes in patients receiving palbociclib for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in Argentina: The IRIS study","volume":"5","author":"Waller","year":"2019","journal-title":"J Glob Oncol"},{"key":"R15-20260331","doi-asserted-by":"crossref","first-page":"16236","DOI":"10.1038\/s41598-021-95758-1","article-title":"Multicentric real world evidence with palbociclib in hormone positive HER2 negative metastatic breast cancer in Indian population","volume":"11","author":"Agrawal","year":"2021","journal-title":"Sci Rep"},{"key":"R16-20260331","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4103\/ijmpo.ijmpo_156_19","article-title":"Letrozole and palbociclib in advanced breast cancer: Outcome from cancer institute, Chennai","volume":"41","author":"Gnanaguru","year":"2020","journal-title":"Indian J Med Paediatr Oncol"},{"key":"R17-20260331","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3332\/ecancer.2022.1450","article-title":"Efficacy of cyclin-dependent kinase 4\/6 inhibitors in patients with metastatic hormone positive breast cancer: A single institutional study from India","volume":"16","author":"Ganguly","year":"2022","journal-title":"Ecancermedicalscience"},{"key":"R18-20260331","doi-asserted-by":"crossref","first-page":"8179","DOI":"10.2147\/CMAR.S325043","article-title":"Matching-adjusted indirect comparison of ribociclib plus fulvestrant versus palbociclib plus letrozole as first-line treatment of HR+\/HER2- advanced breast cancer","volume":"13","author":"Fasching","year":"2021","journal-title":"Cancer Manag Res"},{"key":"R19-20260331","first-page":"291","article-title":"Real-world effectiveness of palbociclib plus endocrine therapy in HR+\/HER2- advanced breast cancer: Final results from the POLARIS trial","author":"Tripathy","year":"2024","journal-title":"Oncologist"},{"key":"R20-20260331","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2147\/PPA.S401480","article-title":"Palbociclib adherence and persistence in patients with hormone receptor positive\/human epidermal growth factor receptor 2 negative (HR+\/HER2-) metastatic breast cancer","volume":"17","author":"Engel-Nitz","year":"2023","journal-title":"Patient Prefer Adherence"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1552_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:41:54Z","timestamp":1787838114000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1552_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1552_25","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-07-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}